Prognostic Factors on the Graft-versus-Host Disease-Free and Relapse-Free Survival after Adult Allogeneic Hematopoietic Stem Cell Transplantation
The cure of hematologic disorders by allogeneic hematopoietic stem cell transplantation (HSCT) is often associated with major complications resulting in poor outcome, including graft-versus-host disease (GVHD), relapse, and death. A novel composite endpoint of GVHD-free/relapse-free survival (GRFS)...
Saved in:
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2016-01-01
|
| Series: | Stem Cells International |
| Online Access: | http://dx.doi.org/10.1155/2016/5143071 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832559928072470528 |
|---|---|
| author | Yao-Chung Liu Sheng-Hsuan Chien Nai-Wen Fan Ming-Hung Hu Jyh-Pyng Gau Chia-Jen Liu Yuan-Bin Yu Liang-Tsai Hsiao Tzeon-Jye Chiou Cheng-Hwai Tzeng Po-Min Chen Jin-Hwang Liu |
| author_facet | Yao-Chung Liu Sheng-Hsuan Chien Nai-Wen Fan Ming-Hung Hu Jyh-Pyng Gau Chia-Jen Liu Yuan-Bin Yu Liang-Tsai Hsiao Tzeon-Jye Chiou Cheng-Hwai Tzeng Po-Min Chen Jin-Hwang Liu |
| author_sort | Yao-Chung Liu |
| collection | DOAJ |
| description | The cure of hematologic disorders by allogeneic hematopoietic stem cell transplantation (HSCT) is often associated with major complications resulting in poor outcome, including graft-versus-host disease (GVHD), relapse, and death. A novel composite endpoint of GVHD-free/relapse-free survival (GRFS) in which events include grades 3-4 acute GVHD, chronic GVHD requiring systemic therapy, relapse, or death is censored to completely characterize the survival without mortality or ongoing morbidity. In this regard, studies attempting to identify the prognostic factors of GRFS are quite scarce. Thus, we reviewed 377 adult patients undergoing allogeneic HSCT between 2003 and 2013. The 1- and 2-year GRFS were 40.8% and 36.5%, respectively, significantly worse than overall survival and disease-free survival (log-rank p<0.001). European Group for Blood and Marrow Transplantation (EBMT) risk score > 2 (p<0.001) and hematologic malignancy (p=0.033) were poor prognostic factors for 1-year GRFS. For 2-year GRFS, EBMT risk score > 2 (p<0.001), being male (p=0.028), and hematologic malignancy (p=0.010) were significant for poor outcome. The events between 1-year GRFS and 2-year GRFS predominantly increased in relapsed patients. With prognostic factors of GRFS, we could evaluate the probability of real recovery following HSCT without ongoing morbidity. |
| format | Article |
| id | doaj-art-bd22e524a8614a7190445fddf05bd493 |
| institution | Kabale University |
| issn | 1687-966X 1687-9678 |
| language | English |
| publishDate | 2016-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Stem Cells International |
| spelling | doaj-art-bd22e524a8614a7190445fddf05bd4932025-02-03T01:28:54ZengWileyStem Cells International1687-966X1687-96782016-01-01201610.1155/2016/51430715143071Prognostic Factors on the Graft-versus-Host Disease-Free and Relapse-Free Survival after Adult Allogeneic Hematopoietic Stem Cell TransplantationYao-Chung Liu0Sheng-Hsuan Chien1Nai-Wen Fan2Ming-Hung Hu3Jyh-Pyng Gau4Chia-Jen Liu5Yuan-Bin Yu6Liang-Tsai Hsiao7Tzeon-Jye Chiou8Cheng-Hwai Tzeng9Po-Min Chen10Jin-Hwang Liu11Division of Hematology, Department of Medicine, Taipei Veterans General Hospital, Taipei 11217, TaiwanDivision of Hematology, Department of Medicine, Taipei Veterans General Hospital, Taipei 11217, TaiwanFaculty of Medicine, National Yang-Ming University, Taipei 11221, TaiwanDivision of Hematology, Department of Medicine, Taipei Veterans General Hospital, Taipei 11217, TaiwanDivision of Hematology, Department of Medicine, Taipei Veterans General Hospital, Taipei 11217, TaiwanDivision of Hematology, Department of Medicine, Taipei Veterans General Hospital, Taipei 11217, TaiwanDivision of Hematology, Department of Medicine, Taipei Veterans General Hospital, Taipei 11217, TaiwanDivision of Hematology, Department of Medicine, Taipei Veterans General Hospital, Taipei 11217, TaiwanDivision of Hematology, Department of Medicine, Taipei Veterans General Hospital, Taipei 11217, TaiwanDivision of Hematology, Department of Medicine, Taipei Veterans General Hospital, Taipei 11217, TaiwanDivision of Hematology, Department of Medicine, Taipei Veterans General Hospital, Taipei 11217, TaiwanDivision of Hematology, Department of Medicine, Taipei Veterans General Hospital, Taipei 11217, TaiwanThe cure of hematologic disorders by allogeneic hematopoietic stem cell transplantation (HSCT) is often associated with major complications resulting in poor outcome, including graft-versus-host disease (GVHD), relapse, and death. A novel composite endpoint of GVHD-free/relapse-free survival (GRFS) in which events include grades 3-4 acute GVHD, chronic GVHD requiring systemic therapy, relapse, or death is censored to completely characterize the survival without mortality or ongoing morbidity. In this regard, studies attempting to identify the prognostic factors of GRFS are quite scarce. Thus, we reviewed 377 adult patients undergoing allogeneic HSCT between 2003 and 2013. The 1- and 2-year GRFS were 40.8% and 36.5%, respectively, significantly worse than overall survival and disease-free survival (log-rank p<0.001). European Group for Blood and Marrow Transplantation (EBMT) risk score > 2 (p<0.001) and hematologic malignancy (p=0.033) were poor prognostic factors for 1-year GRFS. For 2-year GRFS, EBMT risk score > 2 (p<0.001), being male (p=0.028), and hematologic malignancy (p=0.010) were significant for poor outcome. The events between 1-year GRFS and 2-year GRFS predominantly increased in relapsed patients. With prognostic factors of GRFS, we could evaluate the probability of real recovery following HSCT without ongoing morbidity.http://dx.doi.org/10.1155/2016/5143071 |
| spellingShingle | Yao-Chung Liu Sheng-Hsuan Chien Nai-Wen Fan Ming-Hung Hu Jyh-Pyng Gau Chia-Jen Liu Yuan-Bin Yu Liang-Tsai Hsiao Tzeon-Jye Chiou Cheng-Hwai Tzeng Po-Min Chen Jin-Hwang Liu Prognostic Factors on the Graft-versus-Host Disease-Free and Relapse-Free Survival after Adult Allogeneic Hematopoietic Stem Cell Transplantation Stem Cells International |
| title | Prognostic Factors on the Graft-versus-Host Disease-Free and Relapse-Free Survival after Adult Allogeneic Hematopoietic Stem Cell Transplantation |
| title_full | Prognostic Factors on the Graft-versus-Host Disease-Free and Relapse-Free Survival after Adult Allogeneic Hematopoietic Stem Cell Transplantation |
| title_fullStr | Prognostic Factors on the Graft-versus-Host Disease-Free and Relapse-Free Survival after Adult Allogeneic Hematopoietic Stem Cell Transplantation |
| title_full_unstemmed | Prognostic Factors on the Graft-versus-Host Disease-Free and Relapse-Free Survival after Adult Allogeneic Hematopoietic Stem Cell Transplantation |
| title_short | Prognostic Factors on the Graft-versus-Host Disease-Free and Relapse-Free Survival after Adult Allogeneic Hematopoietic Stem Cell Transplantation |
| title_sort | prognostic factors on the graft versus host disease free and relapse free survival after adult allogeneic hematopoietic stem cell transplantation |
| url | http://dx.doi.org/10.1155/2016/5143071 |
| work_keys_str_mv | AT yaochungliu prognosticfactorsonthegraftversushostdiseasefreeandrelapsefreesurvivalafteradultallogeneichematopoieticstemcelltransplantation AT shenghsuanchien prognosticfactorsonthegraftversushostdiseasefreeandrelapsefreesurvivalafteradultallogeneichematopoieticstemcelltransplantation AT naiwenfan prognosticfactorsonthegraftversushostdiseasefreeandrelapsefreesurvivalafteradultallogeneichematopoieticstemcelltransplantation AT minghunghu prognosticfactorsonthegraftversushostdiseasefreeandrelapsefreesurvivalafteradultallogeneichematopoieticstemcelltransplantation AT jyhpynggau prognosticfactorsonthegraftversushostdiseasefreeandrelapsefreesurvivalafteradultallogeneichematopoieticstemcelltransplantation AT chiajenliu prognosticfactorsonthegraftversushostdiseasefreeandrelapsefreesurvivalafteradultallogeneichematopoieticstemcelltransplantation AT yuanbinyu prognosticfactorsonthegraftversushostdiseasefreeandrelapsefreesurvivalafteradultallogeneichematopoieticstemcelltransplantation AT liangtsaihsiao prognosticfactorsonthegraftversushostdiseasefreeandrelapsefreesurvivalafteradultallogeneichematopoieticstemcelltransplantation AT tzeonjyechiou prognosticfactorsonthegraftversushostdiseasefreeandrelapsefreesurvivalafteradultallogeneichematopoieticstemcelltransplantation AT chenghwaitzeng prognosticfactorsonthegraftversushostdiseasefreeandrelapsefreesurvivalafteradultallogeneichematopoieticstemcelltransplantation AT pominchen prognosticfactorsonthegraftversushostdiseasefreeandrelapsefreesurvivalafteradultallogeneichematopoieticstemcelltransplantation AT jinhwangliu prognosticfactorsonthegraftversushostdiseasefreeandrelapsefreesurvivalafteradultallogeneichematopoieticstemcelltransplantation |